La Jolla Pharmaceutical Company (Nasdaq: LJPC) today announced that Niv
E. Caviar, Executive Vice President, Chief Business and Financial
Officer, will present on Tuesday, March 4, at 9:00 am Eastern Time
during the Susquehanna Financial Group Second Annual SIGnificant Options
in Healthcare Conference. On Wednesday, March 5, at 1:00 pm, at the
conference, Matthew Linnik, Ph.D., Executive Vice President and Chief
Scientific Officer, will participate in a panel discussion entitled: "Lupus:
Crossing the Finish Line, New Therapies for SLE.”
The conference will take place at The W Hotel in New York City.
About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company is dedicated to improving and preserving
human life by developing innovative pharmaceutical products. The Company’s
leading product in development is Riquent®,
which is designed to treat lupus renal disease by preventing or delaying
renal flares. Lupus renal disease is a leading cause of sickness and
death in patients with lupus. The Company has also developed potential
small molecule drug candidates to treat various other autoimmune and
inflammatory conditions. The Company’s common
stock is traded on The
Nasdaq Global Market under the symbol LJPC. More
information about the Company is available on its Web site: http://www.ljpc.com.
This press release and the presentations may contain forward-looking
statements within the meaning of the federal securities laws. When used,
the words "anticipate,” "assume,” "believe,” "estimate,” "expect,” "intend,” "may,” "plan,” "project,” "result,” "should,” "will” and similar
expressions that do not relate solely to historical matters identify
forward-looking statements. Forward-looking statements are subject to
risks and uncertainties, both known and unknown and often beyond the
Company’s control, and are not guarantees of
future performance insofar as actual events or results may vary
materially from those anticipated. Factors that may cause such a
variance consist of, among others, those discussed from time to time in
the Company’s filings with the Securities and
Exchange Commission, including the risks described in "Risk
Factors” in the Company’s
Annual Report on Form 10-K for the year ended December 31, 2006, and
specifically the Company’s ability to:
demonstrate sufficiently Riquent’s efficacy
and safety in clinical trials; manufacture Riquent on an adequate scale
for clinical use; or develop further and commercialize Riquent
successfully, either on its own or with a partner. The Company expressly
disclaims any responsibility to update forward-looking statements.
